Abstract B31: Poly(ADP-ribose) Polymerase 1 as a novel target for alpha-particle therapy in high-risk neuroblastoma
Conclusion: 211At-MM4 is a small molecule PARP inhibitor functionalized with an alpha emitting radionuclide astatine-211 that can effectively deliver alpha-particles to the nucleus of cancer cells. The neuroblastoma cell lines evaluated showed differential sensitivities and in vitro results translated into in vivo models. Furthermore we have characterized a novel therapy for high-risk neuroblastoma and aim for future clinical translation.Citation Format: Mehran Makvandi, Catherine Hou, Kuiying Xu, Redmond-Craig Anderson, Samuel Ander-Effron, Robert H. Mach, John M. Maris, Daniel A. Pryma. Poly(ADP-ribose) Polymerase 1 as a novel target for alpha-particle therapy in high-risk neuroblastoma [abstract]. In: Proceedings of the AACR Special Conference on DNA Repair: Tumor Development and Therapeutic Response; 2016 Nov 2-5; Montreal, QC, Canada. Philadelphia (PA): AACR; Mol Cancer Res 2017;15(4_Suppl):Abstract nr B31.
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Makvandi, M., Hou, C., Xu, K., Anderson, R.-C., Ander-Effron, S., Mach, R. H., Maris, J. M., Pryma, D. A. Tags: Therapies Targeting Checkpoints and Mismatch Repair: Poster Presentations - Proffered Abstracts Source Type: research
More News: Cancer | Cancer & Oncology | Conferences | Drugs & Pharmacology | Gastroschisis Repair | Neuroblastoma | Neurology | Pediatrics | Study